Following doxorubicin treatment of breast cancer cells, PRMT5 induces nuclear translocation of the RNA demethylase ALKBH5, which removes m6A methylation from BRCA1 mRNA, stabilizing the transcript and enhancing DNA repair capacity to ultimately attenuate doxorubicin efficacy (33). Here, PRMT5 is linked to breast carcinoma.